Skip to main content
  • Home
  •  Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from HFA 2024

Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from HFA 2024

Topic:
  • Guidelines
  • Structural Heart Disease

Available Credit:

  • 0.50 AMA PRA Credit

Course Published On:

Course Expiry Date:

No ratings

Overview

This course which was recorded at HFA 2024 sees Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, discussing and exploring the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.

This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive analysis of the SEQUOIA trial results; the dynamic evolution of HCM management with forthcoming updates to practice guidelines and expert strategies for seamlessly integrating these evidence-based innovations into clinical practice.

 

Join Dr Coats and Dr Masri as they navigate the forefront of HCM management, offering invaluable insights and actionable strategies to elevate patient care.

Support Statement

This programme is supported by an unrestricted educational grant by Cytokinetics.

Joint Accreditation and Credit Designation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of i3 Health and Radcliffe Medical Education. In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instruction to Participants

There is no fee for taking part in this online learning activity. Activities are designed to be completed within 75 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
 

To complete the course and claim certification participants must:
 

  • Read the course outline information supplied and complete pre-test questions prior to starting the activity.
     
  • Users must read and study the activity in its entirety before completing the post-test questions.
     
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Disclaimer

The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

 

i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labelling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

 

i3 Health and Radcliffe Medical Education planners, reviewers, and managers have nothing to disclosure.

 

i3 Health and Radcliffe have mitigated all relevant financial relationships.

 

Dr Masri discloses he has served as a consultant for: Cytokinetics, BMS, Eidos/BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, and Tenaya.

 

Dr Coats discloses she has served as an advisory board or panel for: Cytokinetics, Roche Diagnostics

Technical/Credit Queries

Technical queries about this activity should be directed to info@radcliffe-group.com. Questions regarding activity credit should be directed to support@i3Health.com.

Target Audience

  • Cardiologists
  • Heart Failure Specialty Physicians
  • Associated Nurses
  • Nurse Practitioners
  • Trainees

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall recent trial data for novel disease modifying therapy in HCM
  • Describe the evolving guideline directed approach to managing HCM
  • Develop an expert-led approach to implementing novel therapy in clinical practice
Register now Log in

Module

Title

Duration

Speakers

Part 1 Emerging Data from HFA 2024: SEQUOIA-HCM 10m 50s Ahmad Masri Caroline Coats
Part 2 Emerging Data from HFA 2024: Posters and Abstracts 2m 16s Ahmad Masri Caroline Coats
Part 3 Guidelines Updates 7m 21s Ahmad Masri Caroline Coats
Part 4 Translation to Clinical Practice 9m 44s Ahmad Masri Caroline Coats
Part 1.

Emerging Data from HFA 2024: SEQUOIA-HCM

Duration: 10m 50s

Speakers: Ahmad Masri Caroline Coats

Part 2.

Emerging Data from HFA 2024: Posters and Abstracts

Duration: 2m 16s

Speakers: Ahmad Masri Caroline Coats

Part 3.

Guidelines Updates

Duration: 7m 21s

Speakers: Ahmad Masri Caroline Coats

Part 4.

Translation to Clinical Practice

Duration: 9m 44s

Speakers: Ahmad Masri Caroline Coats

Course Director

Ahmad Masri

Oregon Health & Science University Medical Group, Portland, USA

Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.

He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.

View full profile

Speaker

Caroline Coats

University of Glasgow, Glasgow, UK

Dr Caroline Coats is an Honorary Clinical Senior Lecturer at the University of Glasgow, Glasgow, UK. 

View full profile
0.50 AMA PRA Credit

0.5 AMA PRA Category 1 Credit™ 

Related Courses

An Expert Interpretation of the ESC Cardiomyopathy Guidelines 2023
  • 1.00 EBAC

Learning objectives

  • Recall guideline updates relevant to the use of disease modifying agents in hypertrophic cardiomyopathy
  • Identify patients who, according to guidelines, may benefit from emerging disease modifying therapies prior to septal ablation therapy or being managed by symptom control alone
  • Discuss long-term management strategies for patients receiving myosin inhibitor therapy
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more